Shah et al. reported four nondiabetic cases of hypomagnesemia successfully treated with SGLT2 inhibitors, suggesting a potential role for these agents in modulating renal magnesium handling beyond glycemic control [4]. The gene discussed is SLC5A2; the disease is familial primary hypomagnesemia.